IL244976B - Use of molecules that bind semphorin-d4 for the treatment of arteriosclerosis - Google Patents

Use of molecules that bind semphorin-d4 for the treatment of arteriosclerosis

Info

Publication number
IL244976B
IL244976B IL244976A IL24497616A IL244976B IL 244976 B IL244976 B IL 244976B IL 244976 A IL244976 A IL 244976A IL 24497616 A IL24497616 A IL 24497616A IL 244976 B IL244976 B IL 244976B
Authority
IL
Israel
Prior art keywords
semaphorin
atherosclerosis
treatment
binding molecules
molecules
Prior art date
Application number
IL244976A
Other languages
English (en)
Hebrew (he)
Other versions
IL244976A0 (en
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of IL244976A0 publication Critical patent/IL244976A0/en
Publication of IL244976B publication Critical patent/IL244976B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL244976A 2013-10-10 2016-04-07 Use of molecules that bind semphorin-d4 for the treatment of arteriosclerosis IL244976B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361889421P 2013-10-10 2013-10-10
PCT/US2014/060129 WO2015054628A1 (en) 2013-10-10 2014-10-10 Use of semaphorin-4d binding molecules for treatment of atherosclerosis

Publications (2)

Publication Number Publication Date
IL244976A0 IL244976A0 (en) 2016-05-31
IL244976B true IL244976B (en) 2020-07-30

Family

ID=52809873

Family Applications (1)

Application Number Title Priority Date Filing Date
IL244976A IL244976B (en) 2013-10-10 2016-04-07 Use of molecules that bind semphorin-d4 for the treatment of arteriosclerosis

Country Status (18)

Country Link
US (1) US9512224B2 (enExample)
EP (1) EP3054976B1 (enExample)
JP (2) JP6760840B2 (enExample)
KR (1) KR102366682B1 (enExample)
CN (1) CN105848679A (enExample)
AU (1) AU2014331683B2 (enExample)
BR (1) BR112016008010A2 (enExample)
CA (1) CA2926944C (enExample)
DK (1) DK3054976T3 (enExample)
EA (1) EA037551B1 (enExample)
ES (1) ES2821814T3 (enExample)
IL (1) IL244976B (enExample)
MX (1) MX385575B (enExample)
NZ (1) NZ630881A (enExample)
PT (1) PT3054976T (enExample)
SG (1) SG11201602807PA (enExample)
WO (1) WO2015054628A1 (enExample)
ZA (1) ZA201602577B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2427212T3 (enExample) 2009-05-08 2018-01-20
CN104168956A (zh) 2011-10-11 2014-11-26 瓦西尼斯公司 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
BR112018071686A2 (pt) 2016-04-22 2019-02-19 Vaccinex, Inc. exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus
WO2018026715A1 (en) 2016-08-02 2018-02-08 Vaccinex, Inc. Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
CN106474559B (zh) * 2016-11-30 2019-07-12 西南交通大学 一种在心血管植入材料表面构建Sema 4D/Heparin微环境的方法
WO2018156509A1 (en) * 2017-02-22 2018-08-30 Vaccinex, Inc. Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases
CN106983919B (zh) * 2017-03-06 2019-07-12 西南交通大学 一种Sema 4D-VEGF涂层的构建方法及应用
CN110636858B (zh) 2017-05-05 2024-03-19 瓦西尼斯公司 人抗脑信号蛋白4d抗体
CN108499220B (zh) * 2018-04-25 2020-07-31 山东纯江环境科技有限公司 石墨烯/聚丙烯非织造布过滤网制备方法及其应用
CN109125731B (zh) * 2018-10-22 2019-10-25 华中科技大学同济医学院附属协和医院 Sema4D/PlexinB1抑制剂在制备治疗及预防眼底血管疾病药物中的应用
US20230238135A1 (en) * 2020-06-19 2023-07-27 The General Hospital Corporation Near-infrared autofluorescence imaging systems and methods
CN117597360A (zh) * 2020-06-25 2024-02-23 瓦西尼斯公司 脑信号蛋白-4d结合分子在rett综合征治疗中的应用
KR102847091B1 (ko) * 2022-08-25 2025-08-21 부산대학교 산학협력단 혈관석회화 동반 만성신부전에서 세마포린 4d의 용도
CN116949097B (zh) * 2023-09-20 2023-12-12 江苏集萃药康生物科技股份有限公司 一种sema4d人源化小鼠模型的构建方法及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO1998046769A1 (en) 1997-04-11 1998-10-22 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
EP0892047A3 (de) 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
AU776865B2 (en) 1998-11-10 2004-09-23 University Of Rochester T cells specific for target antigens and methods and vaccines based thereon
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
JP4524181B2 (ja) 2002-05-30 2010-08-11 マクロジェニクス，インコーポレーテッド Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
RU2006124743A (ru) 2003-12-11 2008-01-20 Дженентек, Инк. (Us) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ДИМЕРИЗАЦИИ И АКТИВАЦИИ с-Мет
US7476724B2 (en) 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
US20060147449A1 (en) 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
EP1871484A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Sema4d in cancer diagnosis, detection and treatment
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
EP2069404B1 (en) * 2007-02-14 2011-01-05 Vaccinex, Inc. Humanized anti-cd100 antibodies
WO2009089461A1 (en) 2008-01-10 2009-07-16 Genentech, Inc. Plexind1 agonists and their use
NO2427212T3 (enExample) 2009-05-08 2018-01-20
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
US8834883B2 (en) 2010-06-14 2014-09-16 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
US9447191B2 (en) 2011-05-13 2016-09-20 National University Corporation Tokyo Medical And Dental University Osteogenesis promoter
CN104168956A (zh) 2011-10-11 2014-11-26 瓦西尼斯公司 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders

Also Published As

Publication number Publication date
EP3054976B1 (en) 2020-07-08
JP2019108359A (ja) 2019-07-04
DK3054976T3 (da) 2020-09-28
WO2015054628A1 (en) 2015-04-16
PT3054976T (pt) 2020-08-05
IL244976A0 (en) 2016-05-31
CN105848679A (zh) 2016-08-10
KR102366682B1 (ko) 2022-02-22
BR112016008010A2 (pt) 2017-09-26
CA2926944A1 (en) 2015-04-16
EA037551B1 (ru) 2021-04-13
CA2926944C (en) 2023-08-08
EP3054976A4 (en) 2017-05-17
AU2014331683B2 (en) 2019-07-11
ZA201602577B (en) 2020-11-25
MX385575B (es) 2025-03-18
US20150104462A1 (en) 2015-04-16
AU2014331683A1 (en) 2016-04-28
JP6760840B2 (ja) 2020-09-23
ES2821814T3 (es) 2021-04-27
EP3054976A1 (en) 2016-08-17
EA201690728A1 (ru) 2016-08-31
KR20160062167A (ko) 2016-06-01
US9512224B2 (en) 2016-12-06
SG11201602807PA (en) 2016-05-30
MX2016004551A (es) 2016-07-22
NZ630881A (en) 2016-03-31
JP2016539089A (ja) 2016-12-15

Similar Documents

Publication Publication Date Title
IL275720A (en) Use of molecules that bind semphorin-D4 for the treatment of neurodegenerative disorders
ZA201602577B (en) Use of semaphorin-4d binding molecules for treatment of atherosclerosis
SG11201507121RA (en) Treatment of cataplexy
AP2015008266A0 (en) 1L-18 binding molecules
EP2879688A4 (en) METHODS OF TREATING ATHEROSCLEROSIS
ZA201508515B (en) Treatment of coal
GB2524707B (en) Small molecules that promote skin regeneration
GB201308466D0 (en) Improved process for treatment of minewater
IL241096B (en) Treatment methods
SG11201605292UA (en) Solubilisation of uv filters
GB201312419D0 (en) Manipulation treatment apparatus
GB201311984D0 (en) Methods and compounds for preventing or treating osteoarthritis
SG11201509238WA (en) Modified collagen molecules
GB2525530B (en) Treatment of hard surfaces
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed